Kareus partners with Quintiles to get conjugate NCEs into clinic
This article was originally published in Scrip
Executive Summary
Kareus Therapeutics, a Switzerland-based biotech company,has entered a strategic alliance with the CRO firm Quintiles to advance two of its preclinical programmes through to clinical trials.